Xia Han - Concepedia

Author

Xia Han

Novartis (United States)

Also Known As

Han Xia, Xia Han, Xia, Han

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)University of Chicago Oregon Health & Science University Medical University of Vienna University of Pennsylvania

About

Xia Han is an author at Novartis (United States) specializing in immunology, hematology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	1.1K
2	Immunology	3	3	1.1K
3	Health Sciences	2	2	539
4	Cell Biology	1	1	542
5	Cellular Therapies	1	1	11

Xia Han

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia Elena J. Orlando, Xia Han, Catherine Tribouley, Nature Medicine Hematological MalignancyMixed-phenotype Acute LeukemiaMalignant Blood DisorderCar19 TherapyImmunology	2018	542
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study Stephen J. Schuster, Constantine S. Tam, Peter Borchmann, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaMedicineLong-term Clinical OutcomesImmunology	2021	528
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia Karen Thudium Mueller, Shannon L. Maude, David L. Porter, Blood	2017	348
PTEN Expression, Not Mutation Status in <i>TSC1, TSC2</i>, or <i>mTOR</i>, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial Martin H. Voss, David Chen, Albert Reising, Clinical Cancer Research	2018	38
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial Jason R. Westin, Constantine S. Tam, Peter Borchmann, Blood	2019	33
Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial Ulrich Jaeger, Michael Bishop, Gilles Salles, Blood	2020	31
Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study. Ulrich Jäger, Nina Worel, Joseph P. McGuirk, Journal of Clinical Oncology Cell TherapyR/r DlbclImmunologyPathologyImmunotherapy	2021	11

Page 1